Last reviewed · How we verify
Intracameral Moxifloxacin 0.1%
Intracameral Moxifloxacin 0.1% is a Fluoroquinolone antibiotic Small molecule drug developed by Suzan A Rattan. It is currently FDA-approved for Prophylaxis of endophthalmitis following cataract surgery, Intracameral antimicrobial prophylaxis in intraocular surgery. Also known as: Auromox.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria. Used for Prophylaxis of endophthalmitis following cataract surgery, Intracameral antimicrobial prophylaxis in intraocular surgery.
At a glance
| Generic name | Intracameral Moxifloxacin 0.1% |
|---|---|
| Also known as | Auromox |
| Sponsor | Suzan A Rattan |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to rapid bactericidal activity against a broad spectrum of bacteria. When administered intracamerally (directly into the anterior chamber of the eye), it achieves high local concentrations to prevent endophthalmitis following cataract surgery.
Approved indications
- Prophylaxis of endophthalmitis following cataract surgery
- Intracameral antimicrobial prophylaxis in intraocular surgery
Common side effects
- Corneal edema
- Anterior chamber inflammation
- Transient vision disturbance
Key clinical trials
- Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery (PHASE2, PHASE3)
- Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change
- Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery (PHASE1)
- A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery (PHASE4)
- Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intracameral Moxifloxacin 0.1% CI brief — competitive landscape report
- Intracameral Moxifloxacin 0.1% updates RSS · CI watch RSS
- Suzan A Rattan portfolio CI
Frequently asked questions about Intracameral Moxifloxacin 0.1%
What is Intracameral Moxifloxacin 0.1%?
How does Intracameral Moxifloxacin 0.1% work?
What is Intracameral Moxifloxacin 0.1% used for?
Who makes Intracameral Moxifloxacin 0.1%?
Is Intracameral Moxifloxacin 0.1% also known as anything else?
What drug class is Intracameral Moxifloxacin 0.1% in?
What development phase is Intracameral Moxifloxacin 0.1% in?
What are the side effects of Intracameral Moxifloxacin 0.1%?
What does Intracameral Moxifloxacin 0.1% target?
Related
- Drug class: All Fluoroquinolone antibiotic drugs
- Target: All drugs targeting Bacterial DNA gyrase and topoisomerase IV
- Manufacturer: Suzan A Rattan — full pipeline
- Therapeutic area: All drugs in Ophthalmology / Infectious Disease
- Indication: Drugs for Prophylaxis of endophthalmitis following cataract surgery
- Indication: Drugs for Intracameral antimicrobial prophylaxis in intraocular surgery
- Also known as: Auromox
- Compare: Intracameral Moxifloxacin 0.1% vs similar drugs
- Pricing: Intracameral Moxifloxacin 0.1% cost, discount & access